Merit Medical: Vegas Takes

Research evidence excerpt

Merit Medical: Vegas Takes

Accessible version

Merit Medical

Vegas Takes

Reiterate Rating: NEUTRAL | PO: 80.00 USD | Price: 62.62 USD

Fireside chat with MMSI CEO and EVP Finance 13 May 2026

We hosted MMSI CEO Martha Aronson and EVP Finance & Treasury Travis McDougal at Equity

our Healthcare conference in Vegas. Key topics included the shift to platform-driven

Travis Steed

segmentation and growth drivers, margin profile across foundational vs therapeutic, Research Analyst

progress toward CGI targets and next strategic plan, WRAPSODY ramp and competitive BofAS +1 404 607 3251

environment, ViewPoint as a tiered strategy in oncology, and M&A focus on tuck-ins travis.steed@bofa.com

within existing platforms. We reiterate our Neutral rating as we look for greater clarity Stephanie Elghazi

on Merit’s long-term growth and margin profile. ResearchBofAS Analyst

stephanie.elghazi@bofa.com

MMSI continuing to become “founder-inspired” Aidan Lahey

On operational changes since the CEO transition, MMSI is continuing their shift from a Research Analyst BofAS

“founder-led” to a more scalable, “founder-inspired” organization. MMSI says the aidan.lahey@bofa.com

capabilities required to grow from a start-up to ~$1.5b in revenue differ from those Enjia Cao

needed to scale beyond that level. MMSI has been focused on streamlining processes to ResearchBofAS Analyst

support scale, establishing eight “platform” teams, each accountable as a mini business enjia.cao@bofa.com

across pipeline development, GTM strategy, OUS expansion, and M&A. A key objective Gracia Mahoney

has been to decentralize decision-making to create a cleaner operating model as the ResearchBofAS Analyst

company matures. It has also added internal resources, hiring in-house reimbursement gracia.mahoney@bofa.com